{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:39:29Z","timestamp":1793410769530,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s10620-026-09870-1","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T07:45:37Z","timestamp":1774943137000},"page":"3709-3716","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety of Statins in an Asian Cohort with Biopsy Proven Metabolic Dysfunction-Associated Steatotic Liver Disease"],"prefix":"10.1007","volume":"71","author":[{"given":"Wei-Lun","family":"Liou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiying","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin Kim-Jun","family":"Teh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark Chang-Chuen","family":"Cheah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Qiang","family":"Leow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony Kiat-Hon","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George Boon-Bee","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"9870_CR1","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77:1335\u20131347. https:\/\/doi.org\/10.1097\/HEP.0000000000000004.","journal-title":"Hepatology."},{"key":"9870_CR2","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S2468-1253(19)30039-1","volume":"4","author":"J Li","year":"2019","unstructured":"Li J, Zou B, Yeo YH et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999\u20132019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4:389\u2013398. https:\/\/doi.org\/10.1016\/S2468-1253(19)30039-1.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"9870_CR3","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1007\/s10620-016-4095-4","volume":"61","author":"GB Goh","year":"2016","unstructured":"Goh GB, McCullough AJ. Natural History of Nonalcoholic Fatty Liver Disease. Dig Dis Sci. 2016;61:1226\u20131233. https:\/\/doi.org\/10.1007\/s10620-016-4095-4.","journal-title":"Dig Dis Sci."},{"key":"9870_CR4","doi-asserted-by":"publisher","unstructured":"European Association for the Study of the Liver (EASL). Electronic address: easloffice@easloffice.eu; European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO); European Association for the Study of the Liver (EASL). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492\u2013542. https:\/\/doi.org\/10.1016\/j.jhep.2024.04.031","DOI":"10.1016\/j.jhep.2024.04.031"},{"key":"9870_CR5","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.cgh.2017.04.039","volume":"15","author":"RG Kim","year":"2017","unstructured":"Kim RG, Loomba R, Prokop LJ, Singh S. Statin Use and Risk of Cirrhosis and Related Complications in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2017;15:1521-1530.e8. https:\/\/doi.org\/10.1016\/j.cgh.2017.04.039.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"9870_CR6","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1053\/j.gastro.2009.01.053","volume":"136","author":"HB El-Serag","year":"2009","unstructured":"El-Serag HB, Johnson ML, Hachem C, Morgana RO. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology. 2009;136:1601\u20131608. https:\/\/doi.org\/10.1053\/j.gastro.2009.01.053.","journal-title":"Gastroenterology."},{"key":"9870_CR7","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/jgh.14794","volume":"35","author":"S Khoo","year":"2020","unstructured":"Khoo S, Wong VW, Goh GB et al. Suboptimal treatment of dyslipidemia in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol. 2020;35:320\u2013325. https:\/\/doi.org\/10.1111\/jgh.14794.","journal-title":"J Gastroenterol Hepatol."},{"key":"9870_CR8","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1111\/apt.16646","volume":"54","author":"JB Henson","year":"2021","unstructured":"Henson JB, Patel YA, Muir AJ. Trends in statin utilisation in US adults with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2021;54:1481\u20131489. https:\/\/doi.org\/10.1111\/apt.16646.","journal-title":"Aliment Pharmacol Ther."},{"key":"9870_CR9","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/hep.22402","volume":"48","author":"CK Argo","year":"2008","unstructured":"Argo CK, Loria P, Caldwell SH, Lonardo A. Statins in liver disease: a molehill, an iceberg, or neither? Hepatology. 2008;48:662\u2013669. https:\/\/doi.org\/10.1002\/hep.22402.","journal-title":"Hepatology."},{"key":"9870_CR10","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/bcp.14943","volume":"88","author":"D Pastori","year":"2022","unstructured":"Pastori D, Pani A, Di Rocco A et al. Statin liver safety in non-alcoholic fatty liver disease: a systematic review and metanalysis. Br J Clin Pharmacol. 2022;88:441\u2013451. https:\/\/doi.org\/10.1111\/bcp.14943.","journal-title":"Br J Clin Pharmacol."},{"key":"9870_CR11","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1053\/j.gastro.2004.02.015","volume":"126","author":"N Chalasani","year":"2004","unstructured":"Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology. 2004;126:1287\u20131292. https:\/\/doi.org\/10.1053\/j.gastro.2004.02.015.","journal-title":"Gastroenterology."},{"key":"9870_CR12","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1016\/S0140-6736(10)61272-X","volume":"376","author":"VG Athyros","year":"2010","unstructured":"Athyros VG, Tziomalos K, Gossios TD et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet. 2010;376:1916\u20131922. https:\/\/doi.org\/10.1016\/S0140-6736(10)61272-X.","journal-title":"Lancet."},{"key":"9870_CR13","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1097\/MCG.0000000000000666","volume":"51","author":"R Jinjuvadia","year":"2017","unstructured":"Jinjuvadia R, Antaki F, Lohia P, Liangpunsakul S. The association between nonalcoholic fatty liver disease and metabolic abnormalities in the United States population. J Clin Gastroenterol. 2017;51:160\u2013166 ([PubMed: 27580477]).","journal-title":"J Clin Gastroenterol."},{"key":"9870_CR14","doi-asserted-by":"publisher","first-page":"e0214","DOI":"10.1097\/MD.0000000000010214","volume":"97","author":"P Golabi","year":"2018","unstructured":"Golabi P, Otgonsuren M, de Avila L, Sayiner M, Rafiq N, Younossi ZM. Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD). Medicine. 2018;97:e0214 ([PubMed: 29595666]).","journal-title":"Medicine."},{"key":"9870_CR15","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1136\/gut.2010.213553","volume":"59","author":"M Stepanova","year":"2010","unstructured":"Stepanova M, Rafiq N, Younossi ZM. Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut. 2010;59:1410\u20131415 ([PubMed: 20660697]).","journal-title":"Gut."},{"key":"9870_CR16","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/MEG.0000000000002517","volume":"35","author":"J Zhang","year":"2023","unstructured":"Zhang J, Fu S, Liu D et al. Statin can reduce the risk of hepatocellular carcinoma among patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2023;35:353\u2013358.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"9870_CR17","doi-asserted-by":"publisher","first-page":"104392","DOI":"10.1016\/j.ebiom.2022.104392","volume":"87","author":"I Ayada","year":"2023","unstructured":"Ayada I, van Kleef LA, Zhang H et al. Dissecting the multifaceted impact of statin use on fatty liver disease: a multidimensional study. EBioMedicine 2023;87:104392.","journal-title":"EBioMedicine"},{"key":"9870_CR18","doi-asserted-by":"publisher","unstructured":"Schreiner AD, Zhang J, Petz CA, et al. Statin prescriptions and progression of advanced fibrosis risk in primary care patients with MASLD. BMJ Open Gastroenterol. 2024;11(1):e001404. Published 2024 Jul 17. https:\/\/doi.org\/10.1136\/bmjgast-2024-001404","DOI":"10.1136\/bmjgast-2024-001404"},{"key":"9870_CR19","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1002\/hep.26156","volume":"57","author":"D Kim","year":"2013","unstructured":"Kim D, Kim WR, Kim HJ, Therneau TM. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology. 2013;57:1357\u20131365. https:\/\/doi.org\/10.1002\/hep.26156.","journal-title":"Hepatology."},{"key":"9870_CR20","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.amjcard.2009.11.023","volume":"105","author":"SM Bradley","year":"2010","unstructured":"Bradley SM, Soine LA, Caldwell JH, Goldberg SL. Screening stress myocardial perfusion imaging and eligibility for liver transplantation. Am J Cardiol 2010;105:1010\u20131013.","journal-title":"Am J Cardiol"},{"key":"9870_CR21","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.jhep.2011.07.023","volume":"56","author":"E Bj\u00f6rnsson","year":"2012","unstructured":"Bj\u00f6rnsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol. 2012;56:374\u2013380. https:\/\/doi.org\/10.1016\/j.jhep.2011.07.023.","journal-title":"J Hepatol."},{"key":"9870_CR22","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/s0168-8278(03)00464-1","volume":"39","author":"L Perger","year":"2003","unstructured":"Perger L, Kohler M, Fattinger K, Flury R, Meier PJ, Pauli-Magnus C. Fatal liver failure with atorvastatin. J Hepatol. 2003;39:1095\u20131097. https:\/\/doi.org\/10.1016\/s0168-8278(03)00464-1.","journal-title":"J Hepatol."},{"key":"9870_CR23","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.amjcard.2005.07.108","volume":"97","author":"C Newman","year":"2006","unstructured":"Newman C, Tsai J, Szarek M, Luo D, Gibson E. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol. 2006;97:61\u201367. https:\/\/doi.org\/10.1016\/j.amjcard.2005.07.108.","journal-title":"Am J Cardiol."},{"key":"9870_CR24","doi-asserted-by":"publisher","unstructured":"Verma SK, Huang J, Hutchinson HG, et al. Statin Use and Severe Acute Liver Injury Among Patients with Elevated Alanine Aminotransferase. Clin Epidemiol. 2022;14:1535\u20131545. Published 2022 Dec 14. https:\/\/doi.org\/10.2147\/CLEP.S385712","DOI":"10.2147\/CLEP.S385712"},{"key":"9870_CR25","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/liv.12988","volume":"36","author":"L Dara","year":"2016","unstructured":"Dara L, Liu ZX, Kaplowitz N. Mechanisms of adaptation and progression in idiosyncratic drug induced liver injury, clinical implications. Liver Int. 2016;36:158\u2013165. https:\/\/doi.org\/10.1111\/liv.12988.","journal-title":"Liver Int."},{"key":"9870_CR26","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1053\/j.gastro.2016.06.055","volume":"151","author":"RA Weersink","year":"2016","unstructured":"Weersink RA, Drenth JP, Borgsteede SD. Altered Pharmacokinetics of Statins Explain Increased Risk of Rhabdomyolysis in Advanced Cirrhosis. Gastroenterology. 2016;151:1036. https:\/\/doi.org\/10.1053\/j.gastro.2016.06.055.","journal-title":"Gastroenterology."},{"key":"9870_CR27","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/jgh.12657","volume":"30","author":"CH Chang","year":"2015","unstructured":"Chang CH, Chang YC, Lee YC, Liu YC, Chuang LM, Lin JW. Severe hepatic injury associated with different statins in patients with chronic liver disease: a nationwide population-based cohort study. J Gastroenterol Hepatol. 2015;30:155\u2013162. https:\/\/doi.org\/10.1111\/jgh.12657.","journal-title":"J Gastroenterol Hepatol."},{"key":"9870_CR28","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1002\/hep.21848","volume":"46","author":"JH Lewis","year":"2007","unstructured":"Lewis JH, Mortensen ME, Zweig S et al. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology. 2007;46:1453\u20131463. https:\/\/doi.org\/10.1002\/hep.21848.","journal-title":"Hepatology."},{"key":"9870_CR29","doi-asserted-by":"publisher","first-page":"408","DOI":"10.37765\/ajmc.2023.89406","volume":"29","author":"AL Cipriani","year":"2023","unstructured":"Cipriani AL, Petz CA, Nielsen EM et al. Statin prescribing patterns in patient-centered medical home patients with NAFLD. Am J Manag Care. 2023;29:408\u2013413. https:\/\/doi.org\/10.37765\/ajmc.2023.89406.","journal-title":"Am J Manag Care."},{"key":"9870_CR30","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/MAJ.0b013e3181e15da8","volume":"340","author":"FS Rzouq","year":"2010","unstructured":"Rzouq FS, Volk ML, Hatoum HH, Talluri SK, Mummadi RR, Sood GK. Hepatotoxicity fears contribute to underutilization of statin medications by pri- mary care physicians. Am. J. Med. Sci. 2010;340:89\u201393.","journal-title":"Am. J. Med. Sci."},{"key":"9870_CR31","doi-asserted-by":"crossref","unstructured":"F. Nascimbeni, J. Aron-Wisnewsky, R. Pais, J. Tordjman, C. Poitou, F. Charlotte, P. Bedossa, T. Poynard, K. Clement, V. Ratziu, L.s. Group, Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease, BMJ Open Gastroenterology 3 (2016) e000075","DOI":"10.1136\/bmjgast-2015-000075"},{"key":"9870_CR32","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.numecd.2016.09.011","volume":"27","author":"M Del Ben","year":"2017","unstructured":"Del Ben M, Baratta F, Polimeni L, Pastori D, Loffredo L, Averna M, Violi F, Angelico F. Under-prescription of statins in patients with non-alcoholic fatty liver disease, Nutrition, metabolism, and cardiovascular diseases. Nutr. Metabol. Cardiovasc. Dis. 2017;27:161\u2013167.","journal-title":"Nutr. Metabol. Cardiovasc. Dis."},{"key":"9870_CR33","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1007\/s10620-015-4000-6","volume":"61","author":"P Blais","year":"2016","unstructured":"Blais P, Lin M, Kramer JR, El-Serag HB, Kanwal F. Statins are underutilized in patients with nonalcoholic fatty liver disease and dyslipidemia. Dig. Dis. Sci. 2016;61:1714\u20131720.","journal-title":"Dig. Dis. Sci."},{"key":"9870_CR34","doi-asserted-by":"crossref","unstructured":"Eslami L, Merat S, Malekzadeh R, Nasseri-Moghaddam S, Aramin H. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Cochrane Database Syst Rev. 2013;12:CD008623","DOI":"10.1002\/14651858.CD008623.pub2"},{"key":"9870_CR35","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.3390\/nu12092762","volume":"12","author":"D Ferro","year":"2020","unstructured":"Ferro D, Baratta F, Pastori D et al. New insights into the pathogenesis of non-alcoholic fatty liver disease: gut-derived lipopolysaccharides and oxidative stress. Nutrients. 2020;12:2762.","journal-title":"Nutrients."},{"key":"9870_CR36","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","volume":"149","author":"E Vilar-Gomez","year":"2015","unstructured":"Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. 2015;149:367-e15. https:\/\/doi.org\/10.1053\/j.gastro.2015.04.005.","journal-title":"Gastroenterology."},{"key":"9870_CR37","doi-asserted-by":"publisher","unstructured":"Zhou XD, Kim SU, Yip TC, et al. Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease. Gut. 2024;73(11):1883\u20131892. Published 2024 Oct 7. https:\/\/doi.org\/10.1136\/gutjnl-2024-333074","DOI":"10.1136\/gutjnl-2024-333074"},{"key":"9870_CR38","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1001\/jama.2024.1447","volume":"331","author":"H Lin","year":"2024","unstructured":"Lin H, Lee HW, Yip TC et al. Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease. JAMA. 2024;331:1287\u20131297. https:\/\/doi.org\/10.1001\/jama.2024.1447.","journal-title":"JAMA."},{"key":"9870_CR39","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.jhep.2015.05.006","volume":"63","author":"P Dongiovanni","year":"2015","unstructured":"Dongiovanni P, Petta S, Mannisto V et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol. 2015;63:705\u2013712. https:\/\/doi.org\/10.1016\/j.jhep.2015.05.006.","journal-title":"J Hepatol."},{"key":"9870_CR40","doi-asserted-by":"publisher","unstructured":"Nascimbeni F, Aron-Wisnewsky J, Pais R, et al. Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease. BMJ Open Gastroenterol. 2016;3(1):e000075. Published 2016 Mar 18. https:\/\/doi.org\/10.1136\/bmjgast-2015-000075","DOI":"10.1136\/bmjgast-2015-000075"},{"key":"9870_CR41","doi-asserted-by":"publisher","first-page":"104392","DOI":"10.1016\/j.ebiom.2022.104392","volume":"87","author":"I Ayada","year":"2023","unstructured":"Ayada I, van Kleef LA, Zhang H et al. Dissecting the multifaceted impact of statin use on fatty liver disease: a multidimensional study. EBioMedicine. 2023;87:104392. https:\/\/doi.org\/10.1016\/j.ebiom.2022.104392.","journal-title":"EBioMedicine."},{"key":"9870_CR42","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/hep.27157","volume":"60","author":"MW Russo","year":"2014","unstructured":"Russo MW, Hoofnagle JH, Gu J et al. Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatology. 2014;60:679\u2013686. https:\/\/doi.org\/10.1002\/hep.27157.","journal-title":"Hepatology."},{"key":"9870_CR43","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1053\/jhep.2003.50229","volume":"37","author":"P Mofrad","year":"2003","unstructured":"Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003;37:1286\u20131292.","journal-title":"Hepatology"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-09870-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-026-09870-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-09870-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T03:01:59Z","timestamp":1787540519000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-026-09870-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["9870"],"URL":"https:\/\/doi.org\/10.1007\/s10620-026-09870-1","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"14 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}